{"title": "European Commission Approves Viread\u00ae for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in Adolescents", "author": null, "url": "https://www.fiercepharma.com/pharma/european-commission-approves-viread%C2%AE-for-hiv-1-infection-children-and-adolescents-and-for", "hostname": "fiercepharma.com", "description": "-- -- Gilead Sciences, Inc.Patrick O'Brien, +1 650-522-1936 (Investors)Stephen Head, +44 (208) 587-2359 (Media, Europe)Cara Miller, +1 650-522-1616 (Media, U.S.) | -- -- Gilead Sciences, Inc.Patrick O'Brien, +1 650-522-1936 (Investors)Stephen Head, +44 (208) 587-2359 (Media, Europe)Cara Miller, +1 650-522-1616 (Media, U.S.)", "sitename": "FiercePharma", "date": "2012-11-28", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}